95 related articles for article (PubMed ID: 14663634)
1. Salvage treatment with docetaxel for recurrent epithelial ovarian cancer.
Niwa Y; Nakanishi T; Kuzuya K; Nawa A; Mizutani S
Int J Clin Oncol; 2003 Dec; 8(6):343-7. PubMed ID: 14663634
[TBL] [Abstract][Full Text] [Related]
2. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy.
Lee JL; Ryu MH; Chang HM; Kim TW; Yook JH; Oh ST; Kim BS; Kim M; Chun YJ; Lee JS; Kang YK
Cancer Chemother Pharmacol; 2008 Apr; 61(4):631-7. PubMed ID: 17520252
[TBL] [Abstract][Full Text] [Related]
4. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer.
Guardiola E; Peyrade F; Chaigneau L; Cupissol D; Tchiknavorian X; Bompas E; Madroszyk A; Ronchin P; Schneider M; Bleuze JP; Blay JY; Pivot X
Eur J Cancer; 2004 Sep; 40(14):2071-6. PubMed ID: 15341981
[TBL] [Abstract][Full Text] [Related]
5. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial.
Kushner DM; Connor JP; Sanchez F; Volk M; Schink JC; Bailey HH; Harris LS; Stewart SL; Fine J; Hartenbach EM;
Gynecol Oncol; 2007 May; 105(2):358-64. PubMed ID: 17258800
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis.
Jo JC; Lee JL; Ryu MH; Sym SJ; Lee SS; Chang HM; Kim TW; Lee JS; Kang YK
Jpn J Clin Oncol; 2007 Dec; 37(12):936-41. PubMed ID: 18211985
[TBL] [Abstract][Full Text] [Related]
7. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE
Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of weekly docetaxel for patients with advanced or recurrent cancer of the cervix.
Pearl ML; Johnston CM; McMeekin DS
Gynecol Obstet Invest; 2007; 64(4):193-8. PubMed ID: 17664880
[TBL] [Abstract][Full Text] [Related]
9. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.
Rodriguez M; Rose PG
Gynecol Oncol; 2001 Nov; 83(2):257-62. PubMed ID: 11606080
[TBL] [Abstract][Full Text] [Related]
10. Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer.
Linch M; Stavridi F; Hook J; Barbachano Y; Gore M; Kaye SB
Gynecol Oncol; 2008 Apr; 109(1):27-32. PubMed ID: 18262259
[TBL] [Abstract][Full Text] [Related]
11. Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?
Miolo G; Bidoli E; Lombardi D; Santeufemia DA; Capobianco G; Dessole F; Scalone S; Spazzapan S; Sorio R; Tabaro G; Veronesi A
Arch Gynecol Obstet; 2012 Feb; 285(2):499-503. PubMed ID: 21735184
[TBL] [Abstract][Full Text] [Related]
12. [First observations of the dose-dense weekly docetaxel therapy in relapsed ovarian cancer].
Lehoczky O; Pulay T
Magy Onkol; 2006; 50(1):43-6. PubMed ID: 16617383
[TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer.
Bhoola SM; Coleman RL; Herzog T; Morris R; Bryant C; Estes JM; Alvarez RD
Gynecol Oncol; 2004 Dec; 95(3):564-9. PubMed ID: 15581964
[TBL] [Abstract][Full Text] [Related]
14. Hematological toxicity of salvage treatment after high-dose chemotherapy and conventional chemotherapy of ovarian cancer.
Vuento MH; Salmi TA; Remes KJ; Grénman SE
Anticancer Res; 2002; 22(2B):1151-5. PubMed ID: 12168916
[TBL] [Abstract][Full Text] [Related]
15. Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer.
Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Blumenson LE
Gynecol Oncol; 1998 Nov; 71(2):190-5. PubMed ID: 9826459
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and hematologic toxicity of salvage chemotherapy following stem cell-supported high-dose chemotherapy in women with recurrent ovarian cancer.
Cook S; Penson R; Duska L; Nikrui N; Goodman A; Fuller A; Seiden M
Gynecol Oncol; 2000 Apr; 77(1):48-54. PubMed ID: 10739690
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study.
Katsumata N; Noda K; Nozawa S; Kitagawa R; Nishimura R; Yamaguchi S; Aoki D; Susumu N; Kuramoto H; Jobo T; Ueki K; Ueki M; Kohno I; Fujiwara K; Sohda Y; Eguchi F
Br J Cancer; 2005 Oct; 93(9):999-1004. PubMed ID: 16234823
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer.
Burger RA; DiSaia PJ; Roberts JA; O'rourke M; Gershenson DM; Homesley HD; Lichtman SM; Barnes W; Moore DH; Monk BJ
Gynecol Oncol; 1999 Feb; 72(2):148-53. PubMed ID: 10021293
[TBL] [Abstract][Full Text] [Related]
19. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer.
Gadducci A; Iacconi P; Cosio S; Fanucchi A; Cristofani R; Riccardo Genazzani A
Gynecol Oncol; 2000 Dec; 79(3):344-9. PubMed ID: 11104603
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
